Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
(2022) In Leukemia 36(4). p.1171-1175
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/b7c705a9-eba0-4e83-bcbf-7874a056eb7e
- author
- publishing date
- 2022
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Leukemia
- volume
- 36
- issue
- 4
- pages
- 1171 - 1175
- publisher
- Nature Publishing Group
- external identifiers
-
- pmid:34974526
- scopus:85122061347
- ISSN
- 0887-6924
- DOI
- 10.1038/s41375-021-01485-x
- language
- English
- LU publication?
- no
- id
- b7c705a9-eba0-4e83-bcbf-7874a056eb7e
- date added to LUP
- 2022-03-03 15:07:48
- date last changed
- 2024-09-19 20:10:00
@article{b7c705a9-eba0-4e83-bcbf-7874a056eb7e, author = {{Sharman, Jeff P. and Egyed, Miklos and Jurczak, Wojciech and Skarbnik, Alan and Pagel, John M. and Flinn, Ian W. and Kamdar, Manali and Munir, Talha and Walewska, Renata and Corbett, Gillian and Fogliatto, Laura Maria and Herishanu, Yair and Banerji, Versha and Coutre, Steven and Follows, George and Walker, Patricia and Karlsson, Karin and Ghia, Paolo and Janssens, Ann and Cymbalista, Florence and Woyach, Jennifer A. and Ferrant, Emmanuelle and Wierda, William G. and Munugalavadla, Veerendra and Yu, Ting and Wang, Min Hui and Byrd, John C.}}, issn = {{0887-6924}}, language = {{eng}}, number = {{4}}, pages = {{1171--1175}}, publisher = {{Nature Publishing Group}}, series = {{Leukemia}}, title = {{Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia}}, url = {{http://dx.doi.org/10.1038/s41375-021-01485-x}}, doi = {{10.1038/s41375-021-01485-x}}, volume = {{36}}, year = {{2022}}, }